A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Official Title

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma


The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

Trial Description

Primary Outcome:

  • Number of Participants with Dose Limiting Toxicities (DLTs)
  • Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)
  • Duration of Response (DoR)
Secondary Outcome:
  • Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3295668
  • PK: AUC of LY3295668 in Combination with Topotecan and Cyclophosphamide
  • Best Overall Response (BOR): Percentage of Participants with CR, PR, Stable Disease (SD), or Progressive Disease (PD)
  • Progression-Free Survival (PFS)
  • Overall Survival (OS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society